Our approach to drug screening is simple: we create physiologically relevant disease models to test drug efficacy using the a variety of cell and tissue sources. This disease complexity is miniaturized and scaled up to meet the expectations of data throughput in mid- to late-drug discovery processes. We develop our technology in microplate format to integrate our technology with established automated workflows. This ensures scalability, as well as time- and resource-efficient assays, while reproducing in vivo like conditions during drug tests.